|
67
|
210
|
3b25A |
Hsp90 alpha n-terminal domain in complex with an inhibitor ch4675194 |
|
67
|
215
|
3b27A |
Hsp90 alpha n-terminal domain in complex with an inhibitor ro4919127 |
|
50
|
149
|
3a0xA |
Catalytic domain of histidine kinase thka (tm1359) (nucleotide free form 1: ammomium phosphate, monoclinic) |
|
56
|
152
|
3a0zA |
Catalytic domain of histidine kinase thka (tm1359) (nucleotide free form 4: isopropanol, orthorombic) |
|
55
|
152
|
3a0wA |
Catalytic domain of histidine kinase thka (tm1359) for mad phasing (nucleotide free form 2, orthorombic) |
|
56
|
152
|
3a0tA |
Catalytic domain of histidine kinase thka (tm1359) in complex with adp and mg ion (trigonal) |
|
55
|
149
|
3a0yA |
Catalytic domain of histidine kinase thka (tm1359) (nucleotide free form 3: 1,2-propanediol, orthorombic) |
|
74
|
341
|
3a0rA |
Crystal structure of histidine kinase thka (tm1359) in complex with response regulator protein trra (tm1360) |
|
110
|
366
|
2zdxA |
Inhibitor-bound structures of human pyruvate dehydrogenase kinase 4 |
|
117
|
506
|
2zbkB |
Crystal structure of an intact type ii dna topoisomerase: insights into dna transfer mechanisms |
|
128
|
378
|
2zkjA |
Crystal structure of human pdk4-adp complex |
|
123
|
368
|
2zdyA |
Inhibitor-bound structures of human pyruvate dehydrogenase kinase 4 |
|
65
|
208
|
2yejA |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
59
|
208
|
2yebA |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
68
|
208
|
2ye6A |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
62
|
210
|
2yi5A |
Structural characterization of 5-aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole hsp90 inhibitors. |
|
67
|
208
|
2yecA |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
67
|
208
|
2ye7A |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
66
|
208
|
2yedA |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
68
|
207
|
2yjxA |
Tricyclic series of hsp90 inhibitors |
|
65
|
208
|
2ye2A |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
66
|
207
|
2ykiA |
Tricyclic series of hsp90 inhibitors |
|
69
|
214
|
2ygaA |
E88g-n92l mutant of n-term hsp90 complexed with geldanamycin |
|
66
|
208
|
2ye9A |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
70
|
216
|
2yefA |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
63
|
208
|
2ye5A |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
69
|
207
|
2yk9A |
Tricyclic series of hsp90 inhibitors |
|
65
|
209
|
2yi6A |
Structural characterization of 5-aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole hsp90 inhibitors. |
|
64
|
208
|
2yegA |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
68
|
207
|
2ykjA |
Tricyclic series of hsp90 inhibitors |
|
66
|
207
|
2ykeA |
Tricyclic series of hsp90 inhibitors |
|
68
|
214
|
2ygeA |
E88g-n92l mutant of n-term hsp90 complexed with geldanamycin |
|
61
|
208
|
2yeiA |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
63
|
208
|
2yeeA |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
69
|
207
|
2ykcA |
Tricyclic series of hsp90 inhibitors |
|
67
|
207
|
2yjwA |
Tricyclic series of hsp90 inhibitors |
|
68
|
209
|
2yi7A |
Structural characterization of 5-aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole hsp90 inhibitors. |
|
65
|
208
|
2yehA |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
69
|
207
|
2yk2A |
Tricyclic series of hsp90 inhibitors |
|
70
|
207
|
2ykbA |
Tricyclic series of hsp90 inhibitors |
|
71
|
213
|
2ygfA |
L89v, l93i and v136m mutant of n-term hsp90 complexed with geldanamycin |
|
66
|
209
|
2yi0A |
Structural characterization of 5-aryl-4-(5-substituted-2-4- dihydroxyphenyl)-1,2,3-thiadiazole hsp90 inhibitors. |
|
66
|
208
|
2ye3A |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
69
|
208
|
2yeaA |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
66
|
208
|
2ye8A |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
63
|
208
|
2ye4A |
Hsp90 inhibitors and drugs from fragment and virtual screening |
|
69
|
214
|
2xx2A |
Macrolactone inhibitor bound to hsp90 n-term |
|
65
|
214
|
2xx5A |
Macrolactone inhibitor bound to hsp90 n-term |
|
69
|
214
|
2xx4A |
Macrolactone inhibitor bound to hsp90 n-term |
|
65
|
213
|
2xjgA |
Structure of hsp90 with small molecule inhibitor bound |
